Overcoming Limitations with Transient Protein Expression to Accelerate Development
November 1, 2022
Tags:
In this Q&A, MaxCyte's Chief Scientific Officer Cenk Sumen discusses how extending the use of transient protein expression to later in development can allow developers to fail fast and confidently, thus accelerating program success.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
.svg)
